Evidence map›Paper›PMID 38261950›Full record

ArticleMolecular therapy. Nucleic acids2024

AAV-based gene editing of type 1 collagen mutation to treat osteogenesis imperfecta.

Yeon-Suk Yang, Tadatoshi Sato, Sachin Chaugule, Hong Ma, Jun Xie, Guangping Gao, Jae-Hyuck Shim

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. [Comprehensive considerations for the diagnosis, treatment, and management of osteogenesis imperfecta].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yeon-Suk YangDepartment of Medicine, Division of Rheumatology, UMass Chan Medical School, Worcester, MA 01655, USA.
Tadatoshi SatoDepartment of Medicine, Division of Rheumatology, UMass Chan Medical School, Worcester, MA 01655, USA.
Sachin ChauguleDepartment of Medicine, Division of Rheumatology, UMass Chan Medical School, Worcester, MA 01655, USA.
Hong MaHorae Gene Therapy Center, UMass Chan Medical School, Worcester, MA 01655, USA.
Jun XieHorae Gene Therapy Center, UMass Chan Medical School, Worcester, MA 01655, USA.
Guangping GaoHorae Gene Therapy Center, UMass Chan Medical School, Worcester, MA 01655, USA.
Jae-Hyuck ShimDepartment of Medicine, Division of Rheumatology, UMass Chan Medical School, Worcester, MA 01655, USA.
University of Massachusetts Chan Medical School · US

Funding

Project 4: A permanent off-switch for AAVU19AI149646 · NIAID · UNIVERSITY OF FLORIDA · PI FARZAN, MICHAEL R. · 2020 to 2024
$14.0M
Viral Vector CoreP01HL131471 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI XUE, WEN · 2016 to 2020
$11.3M
Sustained antibody delivery for durable suppression of immunodeficiency virus replicationR01AI121135 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2015 to 2026
$6.9M
Oligodendrocyte-focused rAAV gene therapy strategies for Canavan disease and LeukodystrophiesR01NS076991 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Guangping Gao · 2012 to 2026
$5.7M
Next Generation of Recombinant AAV Serotype Vectors for Gene TherapyR01HL097088 · NHLBI · UNIVERSITY OF FLORIDA · PI GAO, GUANGPING, HERZOG, ROLAND W. · 2010 to 2018
$5.4M
Develop combinatorial non-viral and viral CRISPR delivery for lung diseasesUH3HL147367 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANDERSON, DANIEL G, GAO, GUANGPING · 2021 to 2022
$2.9M
Develop combinatorial non-viral and viral CRISPR delivery for lung diseasesUG3HL147367 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANDERSON, DANIEL G, GAO, GUANGPING · 2018 to 2020
$2.7M
Fortilin, CTNNA3, and the HeartR01HL152723 · NHLBI · UNIVERSITY OF WASHINGTON · PI FUJISE, KEN · 2021 to 2024
$2.7M
Developing and evaluating bone targeting agents to mimic the skeletal effects of mechanical loadingR21AR079633 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SATO, TADATOSHI · 2022 to 2023
$457k
NHLBI NIH HHS P01 HL131471NHLBI NIH HHS R01 HL097088NHLBI NIH HHS R01 HL152723NHLBI NIH HHS UG3 HL147367NHLBI NIH HHS UH3 HL147367NIAID NIH HHS R01 AI121135NIAID NIH HHS U19 AI149646NIAMS NIH HHS R21 AR079633NINDS NIH HHS R01 NS076991
6 · The paper itself

Abstract

Osteogenesis imperfecta (OI) is a genetic disorder characterized by bone fragility, low bone mass, fractures, and extraskeletal manifestations. Since OI is commonly caused by single-nucleotide mutation(s) in the

Indexed as

AAVboneCRISPR-Cas9GeneRideMT: RNA/DNA Editingosteoblastsosteogenesis imperfectatype 1 collagen

Identifiers

PMID38261950
PMCPMC10797194
OpenAlexW4390238701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.